Peptidomimetic thrombin inhibitors
Drug development review published in Pathophysiol Haemost Thromb (2005)
Abstract
The central position of thrombin in the coagulation cascade has made it a popular target for discovery of novel antithrombotic agents. Starting with hirudin, a natural peptide isolated from the medicinal leech, its shorter synthetic analogue hirulog, and argatroban,the first therapeutically used synthetic small-molecule thrombin active site inhibitor, hundreds of direct thrombin inhibitors have been discovered over the last 20 years. Most of them are peptidomimetic compounds,based on the amino acid sequence of fibrinogen which binds into the thrombin active site. Since elucidation of the crystal structure of human thrombin in 1989, the structure-based design of low-molecular-weight peptidomimetic thrombin inhibitors has been greatly aided by the use of x-ray crystallographic analysis of thrombin-inhibitor complexes. The ultimate goal of most research programmes and drug optimization strategies is to develop an orally bioavailable, small-molecule,direct thrombin inhibitor that would be suitable for once or twice daily dosing. An overview of the most advanced peptidomimetic direct thrombin inhibitors bivalirudin, argatroban, ximelagatran and dabigatran is presented.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Reviews the development of direct thrombin inhibitors starting from leech-derived hirudin and its synthetic peptidomimetic descendants — hirulog, argatroban, bivalirudin, ximelagatran, dabigatran — culminating in orally bioavailable small-molecule scaffolds.
Why This Matters for Hirudotherapy
This review article surveys the development of peptidomimetic direct thrombin inhibitors, tracing the field from its origins in hirudin—the natural anticoagulant peptide isolated from the medicinal leech—through synthetic analogues like hirulog and small-molecule inhibitors such as argatroban, to advanced agents including bivalirudin, ximelagatran, and dabigatran. For ASH and hirudotherapy, this overview is directly relevant because it documents how the leech-derived hirudin served as the foundational template for an entire class of clinically important anticoagulants, underscoring the enduring pharmacological legacy of leech-secreted compounds in modern thrombosis management. The abstract also notes how crystallographic analysis of thrombin–inhibitor complexes has guided structure-based drug design toward orally bioavailable agents. A caveat: this is a narrative review, not original experimental or clinical data, so it synthesizes existing literature rather than providing new efficacy evidence.
Citation
Peptidomimetic thrombin inhibitors.
Kikelj D · Pathophysiology of haemostasis and thrombosis, 2005
Added to ASH library: May 26, 2026 · Site last updated: June 18, 2026